Ipratropium
- Generic Name
- Ipratropium
- Brand Names
- Atrovent, Combivent, Ipravent
- Drug Type
- Small Molecule
- Chemical Formula
- C20H30NO3
- CAS Number
- 60205-81-4
- Unique Ingredient Identifier
- GR88G0I6UL
- Background
Ipratropium is a quaternary ammonium derivative of atropine that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.
...
- Indication
Inhaled ipratropium is indicated in combination with inhaled beta-agonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatment.
Asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flow.
...
- Associated Conditions
- Acute Exacerbation of Asthma, Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD), Nasal Congestion Associated With the Common Cold, Non-Allergic Rhinitis, Perennial Allergic Rhinitis (PAR), Rhinitis
- Associated Therapies
- -
A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy
- Conditions
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-04-22
- Target Recruit Count
- 1050
- Registration Number
- NCT06376942
- Locations
- 🇮🇳
Bronchoscopy suite, PGIMER, Chandigarh, India
Treating Respiratory Emergencies in Children Study
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 150
- Registration Number
- NCT06074185
- Locations
- 🇺🇸
Mecklenburg County EMS, Charlotte, North Carolina, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
🇺🇸University at Buffalo, Buffalo, New York, United States
Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Hat Yai Medical Education Center
- Target Recruit Count
- 60
- Registration Number
- NCT05550402
- Locations
- 🇹🇭
Hatyai Hospital, Hat Yai, Songkhla, Thailand
Defining and Treating Depression-related Asthma
- Conditions
- Interventions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 40
- Registration Number
- NCT04617015
- Locations
- 🇺🇸
Women and Children's Hospital of Buffalo, Buffalo, New York, United States
Revefenacin in Acute Respiratory Insufficiency in COPD
- Conditions
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 21
- Registration Number
- NCT04315558
- Locations
- 🇺🇸
Ronald Reagan Medical Center at UCLA, Los Angeles, California, United States
🇺🇸Santa Monica UCLA, Santa Monica, California, United States
Ipratropium Bromide Spray as Treatment for Sialorrhea in Children
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- London Health Sciences Centre
- Target Recruit Count
- 30
- Registration Number
- NCT03747536
Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 100
- Registration Number
- NCT03296579
Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT03219866
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT03136120
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus
- Conditions
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02872597
- Locations
- 🇺🇸
Rainbow Babies and Children's Hospital (of Univ. Hospitals Case Med. Center), Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.